Kyle O'Neil
@kylemoneil
Venture Analyst @JNJInnovation. Former life science consultant and @pennbioeng student + @PennPCI Fellow. Lover of all sports and sciences. Views are my own.
You might like
Column: Fighting Parkinson’s one punch at a time…(spoiler alert…one of the boxers is me,) latimes.com/sports/story/2…
A final soliloquy of many deserving of a listen from all - thanks for the memories and inspiration @TonyReali @AroundtheHorn
At yesterday's opening ceremony, we asked the cancer community to stand together to make their voices heard in support of innovative cancer science and medicine. #CancerResearchSavesLives® #AACR25
Kevan M. Shokat, PhD, discusses "Overcoming the Undruggable Nature of K-Ras" in the #AACR25 Opening Plenary Session. @kevansf
Can we see into the future? Find out on 3/18 at BIO-Europe, when Fiona MacLaughlin, Senior Director, Venture Investments will be speaking on how the pharma industry can reshape its pipeline to keep pace with market needs. Learn more here: jji.jnj/4b5lK6Q
Discover how Johnson & Johnson Innovation–JJDC, Inc., the corporate VC organization of J&J, is making strategic investments to advance transformative healthcare solutions in our 2024 Year in review: jji.jnj/3WAW7oz #JNJ #MyCompany #JPM25
Asish Xavier discussed the potential of biotech investments for 2025 at the BIO Investor Forum in San Francisco. As a veteran investor, he shared valuable insights into industry trends and IPOs on the horizon. Read the full article here! jji.jnj/3YoKHEd
Overdue congratulations to @mpreminger, who offered thought provoking words receiving the @kendallnow inaugural Founders’ Award: “Serve a purpose and not a person… innovation is a team sport” Pictured: the award ceremony & my 1st day! Congratulations to @snbhatia as well!
Bringing together commercial players, investors and dealmakers, Asish Xavier lends his insights as a biotech investor at the @BioCentury Grand Rounds breakfast workshop to discuss commercialization strategy.
HistoSonics, whose technology uses high-intensity sound waves to destroy tumors of the liver, has raised $102 million in new funding wsj.com/articles/histo…
In one of the best biotech reads from July, @ky_lahucik of @endpts accurately captures growing optimism on the sector rebound given the increasing interest of emerging biopharma’s in M&A 'Next-gen' biotech acquirers find M&A momentum in Q2 - endpts.com/next-gen-biote…
On today’s #BiotechHangout, hosts @biotech1, @SamFazeli8, @BrianSkorney, @mpreminger and @ericschmidt151 discuss the strong month for the $XBI, earnings highlights, as well as obesity updates from $RHHBY and $VKTX, topical gene therapy from $KRYS, rare disease news including new…
Three week later and it still feels SO GOOD, SO GOOD, SO GOOD! @celtics @FCHWPO @Flash_Gordon96 #MVP #runitback #DifferentHere
Great breakdown of the #APOE gene in #Alzheimers by @RLCscienceboss!
Scientists just discovered a new genetic clue for delaying #Alzheimers disease. It’s already inspiring drug discovery. Read more in my story for @endpts about how scientists are designing drugs that mimic the protective APOE3 Christchurch mutation. endpts.com/scientists-jus…
Great interview from @delafuenteupenn of @pennbioeng!
Thank you @NatureBiotech for this wonderful and deeply personal interview, where I had the opportunity to share my experiences and my dream of using AI for antibiotic discovery.
Greetings, BioTwitter hockey fans. Our Stanley Cup playoff bracket is back for the nth time - sadly, I've not kept track. League is below. DM for password. Game on. Almost. bracketchallenge.nhl.com/leagues/league…
For readers interested in radiopharmaceuticals, this recent article in @bpdealmakers assesses dealmaking and financing activity in the field bit.ly/4cmoIUE
Targeted degradation of extracellular and membrane proteins is being pursued with therapeutic platforms including sweeping antibodies, LYTACs, ATACs, AbTACs, PROTABs and KineTACs - find out more in this review in the February issue bit.ly/489BXVZ rdcu.be/dtT1P
Always love seeing good things from Philly biotech, including the awesome team at @IntegralMoleclr
Cool paper for Saturday reading: Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets. Really great tables, make sure you grab the supplementary excel as well. ncbi.nlm.nih.gov/pmc/articles/P…
Great context on targeting #MALT1 from @JDMontagu at @hotspotthera Signaling Complexes: A Ripe Opportunity for Drug Development lifescivc.com/2024/01/signal…
United States Trends
- 1. Bama 18.2K posts
- 2. #UFC322 32.9K posts
- 3. Oklahoma 27.6K posts
- 4. Ty Simpson 3,731 posts
- 5. Jeremiah Smith 1,743 posts
- 6. Boomer Sooner 2,004 posts
- 7. Wingo N/A
- 8. #AEWCollision 3,090 posts
- 9. Iowa 19.3K posts
- 10. Noah Thomas N/A
- 11. Sabatini 1,364 posts
- 12. Mateer 3,165 posts
- 13. UConn 4,408 posts
- 14. Brent Venables 1,417 posts
- 15. Jungkook 256K posts
- 16. #RollTide 3,232 posts
- 17. Lagway N/A
- 18. Heisman 11.1K posts
- 19. #Svengoolie N/A
- 20. Kyle Daukaus N/A
Something went wrong.
Something went wrong.